{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T15:49:07Z","timestamp":1792079347611,"version":"4.4.0"},"reference-count":47,"publisher":"American Chemical Society (ACS)","issue":"9","license":[{"start":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T00:00:00Z","timestamp":1788652800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T00:00:00Z","timestamp":1788652800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T00:00:00Z","timestamp":1788652800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-045"}],"funder":[{"DOI":"10.13039\/501100004206","name":"Osaka University","doi-asserted-by":"publisher","award":["2024A6909"],"award-info":[{"award-number":["2024A6909"]}],"id":[{"id":"10.13039\/501100004206","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004206","name":"Osaka University","doi-asserted-by":"publisher","award":["2024B6909"],"award-info":[{"award-number":["2024B6909"]}],"id":[{"id":"10.13039\/501100004206","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["1R01CA285402"],"award-info":[{"award-number":["1R01CA285402"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007059","name":"Northwestern University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007059","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Pancreatic ductal adenocarcinoma (PDAC) is highly lethal and remains largely refractory to targeted therapy despite its near-universal dependence on oncogenic KRAS. Single-agent KRAS inhibitors often fail due to adaptive resistance mechanisms that emerge under pharmacologic pressure. Previous studies combining MAP2K4 inhibition with KRASG12C-targeted therapy determined that partial JNK suppression can enhance anticancer responses. Here, we extend this concept to PDAC, which is predominantly driven by KRASG12D mutations, and demonstrate that full JNK pathway inactivation restores sensitivity to KRAS inhibition in resistant cells. Using selective MAP2K4, MAP2K7, or combined inhibitors, we show that more extensive JNK suppression disables the feedback loop that reactivates KRAS signaling. In contrast, KRASG12D inhibitor-sensitive cells derive no benefit from JNK pathway inhibition, revealing a resistance-specific vulnerability amenable to therapeutic exploitation.<\/jats:p>","DOI":"10.1021\/acschembio.6c00580","type":"journal-article","created":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T03:01:34Z","timestamp":1788750094000},"page":"2466-2476","source":"Crossref","is-referenced-by-count":0,"title":["Exploiting Acquired Drug Resistance in Pancreatic Cancer through Selective Covalent Targeting of MAP2K4\/7"],"prefix":"10.1021","volume":"21","author":[{"given":"Gina M.","family":"Connors","sequence":"first","affiliation":[{"name":"Northwestern University , , , ,","place":["Evanston, Illinois, United States, 60208"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thao D.","family":"Pham","sequence":"additional","affiliation":[{"name":"Northwestern University , , , ,","place":["Chicago, Illinois, United States, 60611"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey H.","family":"Becker","sequence":"additional","affiliation":[{"name":"Northwestern University , , , ,","place":["Chicago, Illinois, United States, 60611"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aria A.","family":"Argus","sequence":"additional","affiliation":[{"name":"Northwestern University , , , ,","place":["Evanston, Illinois, United States, 60208"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenkichi","family":"Baba","sequence":"additional","affiliation":[{"name":"Osaka Metropolitan University , , , ,","place":["Sakai, Osaka, Japan, 599-8531"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayoshi","family":"Kinoshita","sequence":"additional","affiliation":[{"name":"Osaka Metropolitan University , , , ,","place":["Sakai, Osaka, Japan, 599-8531"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidayatullah G.","family":"Munshi","sequence":"additional","affiliation":[{"name":"Northwestern University , , , ,","place":["Chicago, Illinois, United States, 60611"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4856-3569","authenticated-orcid":true,"given":"Karl A.","family":"Scheidt","sequence":"additional","affiliation":[{"name":"Northwestern University , , , ,","place":["Evanston, Illinois, United States, 60208"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2026,9,6]]},"reference":[{"issue":"1","key":"2026101511073657700_cit1","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1186\/s12885-018-4610-4","article-title":"Trends in Pancreatic Adenocarcinoma Incidence and Mortality in the United States in the Last Four Decades; a SEER-Based Study","volume":"18","author":"Saad","year":"2018","journal-title":"BMC Cancer"},{"issue":"10039","key":"2026101511073657700_cit2","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S0140-6736(16)00141-0","article-title":"Pancreatic Cancer","volume":"388","author":"Kamisawa","year":"2016","journal-title":"Lancet"},{"issue":"43","key":"2026101511073657700_cit3","doi-asserted-by":"publisher","first-page":"4846","DOI":"10.3748\/wjg.v24.i43.4846","article-title":"Pancreatic Cancer: A Review of Clinical Diagnosis, Epidemiology, Treatment and Outcomes","volume":"24","author":"McGuigan","year":"2018","journal-title":"World J. Gastroenterol."},{"issue":"4","key":"2026101511073657700_cit4","doi-asserted-by":"publisher","first-page":"332","DOI":"10.3978\/j.issn.1000-9604.2015.06.07","article-title":"Pancreatic Cancer Surgery: Past, Present, and Future","volume":"27","author":"Griffin","year":"2015","journal-title":"Chin. J. Cancer Res."},{"issue":"11","key":"2026101511073657700_cit5","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1002\/bjs.4794","article-title":"Current Standards of Surgery for Pancreatic Cancer","volume":"91","author":"Alexakis","year":"2004","journal-title":"Br. J. Surg."},{"issue":"7","key":"2026101511073657700_cit6","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.3390\/ijms18071338","article-title":"Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies","volume":"18","author":"Adamska","year":"2017","journal-title":"Int. J. Mol. Sci."},{"issue":"5888","key":"2026101511073657700_cit7","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/300149a0","article-title":"A Point Mutation Is Responsible for the Acquisition of Transforming Properties by the T24 Human Bladder Carcinoma Oncogene","volume":"300","author":"Reddy","year":"1982","journal-title":"Nature"},{"issue":"5894","key":"2026101511073657700_cit8","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1038\/300762a0","article-title":"Activation of the T24 Bladder Carcinoma Transforming Gene Is Linked to a Single Amino Acid Change","volume":"300","author":"Taparowsky","year":"1982","journal-title":"Nature"},{"issue":"4","key":"2026101511073657700_cit9","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/0092-8674(88)90571-5","article-title":"Most Human Carcinomas of the Exocrine Pancreas Contain Mutant cK-Ras Genes","volume":"53","author":"Almoguera","year":"1988","journal-title":"Cell"},{"issue":"5897","key":"2026101511073657700_cit10","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1126\/science.1164368","article-title":"Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses","volume":"321","author":"Jones","year":"2008","journal-title":"Science"},{"issue":"1","key":"2026101511073657700_cit11","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41698-024-00505-0","article-title":"Impact of KRAS Mutations and Co-Mutations on Clinical Outcomes in Pancreatic Ductal Adenocarcinoma","volume":"8","author":"Yousef","year":"2024","journal-title":"npj Precis. Oncol."},{"issue":"2","key":"2026101511073657700_cit12","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.trecan.2024.11.009","article-title":"KRAS Inhibitors: Resistance Drivers and Combinatorial Strategies","volume":"11","author":"Isermann","year":"2025","journal-title":"Trends Cancer"},{"issue":"7","key":"2026101511073657700_cit13","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1158\/2159-8290.CD-25-0349","article-title":"Response and Resistance to RAS Inhibition in Cancer","volume":"15","author":"Ebright","year":"2025","journal-title":"Cancer Discov."},{"issue":"11","key":"2026101511073657700_cit14","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1158\/2159-8290.CD-24-0177","article-title":"Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer","volume":"14","author":"Dilly","year":"2024","journal-title":"Cancer Discov."},{"key":"2026101511073657700_cit15","doi-asserted-by":"publisher","first-page":"355","DOI":"10.3389\/fphys.2012.00355","article-title":"Crosstalk and Signaling Switches in Mitogen-Activated Protein Kinase Cascades","volume":"3","author":"Fey","year":"2012","journal-title":"Front. Physiol."},{"issue":"22","key":"2026101511073657700_cit16","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1038\/sj.onc.1210421","article-title":"MAP Kinase Signalling Pathways in Cancer","volume":"26","author":"Dhillon","year":"2007","journal-title":"Oncogene"},{"issue":"3","key":"2026101511073657700_cit17","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.3892\/etm.2020.8454","article-title":"ERK\/MAPK Signalling Pathway and Tumorigenesis","volume":"19","author":"Guo","year":"2020","journal-title":"Exp. Ther. Med."},{"issue":"1","key":"2026101511073657700_cit18","doi-asserted-by":"publisher","first-page":"198","DOI":"10.3390\/cells9010198","article-title":"Targeting Aberrant RAS\/RAF\/MEK\/ERK Signaling for Cancer Therapy","volume":"9","author":"Degirmenci","year":"2020","journal-title":"Cells"},{"issue":"8","key":"2026101511073657700_cit19","doi-asserted-by":"publisher","first-page":"7495","DOI":"10.3390\/ijms24087495","article-title":"MKK4 Inhibitors\u2014Recent Development Status and Therapeutic Potential","volume":"24","author":"Katzengruber","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"2026101511073657700_cit20","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.chembiol.2018.10.011","article-title":"Covalent Docking Identifies a Potent and Selective MKK7 Inhibitor","volume":"26","author":"Shraga","year":"2019","journal-title":"Cell Chem. Biol."},{"issue":"5","key":"2026101511073657700_cit21","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1021\/acsmedchemlett.3c00029","article-title":"Rational Design of Highly Potent and Selective Covalent MAP2K7 Inhibitors","volume":"14","author":"Kim","year":"2023","journal-title":"ACS Med. Chem. Lett."},{"issue":"5","key":"2026101511073657700_cit22","doi-asserted-by":"publisher","first-page":"2843","DOI":"10.1021\/acs.jmedchem.9b00102","article-title":"Targeting the MKK7\u2013JNK (Mitogen-Activated Protein Kinase Kinase 7\u2013c-Jun N-Terminal Kinase) Pathway with Covalent Inhibitors","volume":"62","author":"Wolle","year":"2019","journal-title":"J. Med. Chem."},{"issue":"10","key":"2026101511073657700_cit23","doi-asserted-by":"publisher","first-page":"11687","DOI":"10.1021\/acs.jmedchem.6c00689","article-title":"Darizmetinib (HRX215): A Promising 1st-in-Class Liver Regenerating Drug in Phase 1b\/2a Clinical Development, Targeting the Stress Signaling Protein Kinase MKK4","volume":"69","author":"Albrecht","year":"2026","journal-title":"J. Med. Chem."},{"issue":"7","key":"2026101511073657700_cit24","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1016\/j.cell.2024.02.023","article-title":"First-in-Class MKK4 Inhibitors Enhance Liver Regeneration and Prevent Liver Failure","volume":"187","author":"Zwirner","year":"2024","journal-title":"Cell"},{"issue":"1","key":"2026101511073657700_cit25","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/1471-2407-11-173","article-title":"Analysis of the Mitogen-Activated Protein Kinase Kinase 4 (MAP2K4) Tumor Suppressor Gene in Ovarian Cancer","volume":"11","author":"Davis","year":"2011","journal-title":"BMC Cancer"},{"issue":"21","key":"2026101511073657700_cit26","doi-asserted-by":"publisher","first-page":"4270","DOI":"10.1128\/MCB.05562-11","article-title":"Map2k4 Functions as a Tumor Suppressor in Lung Adenocarcinoma and Inhibits Tumor Cell Invasion by Decreasing Peroxisome Proliferator-Activated Receptor \u03932 Expression","volume":"31","author":"Ahn","year":"2011","journal-title":"Mol. Cell Biol."},{"issue":"14","key":"2026101511073657700_cit27","doi-asserted-by":"publisher","first-page":"5797","DOI":"10.1158\/0008-5472.CAN-09-3669","article-title":"The Mitogen-Activated Protein Kinase Kinase 4 Has a Pro-Oncogenic Role in Skin Cancer","volume":"70","author":"Finegan","year":"2010","journal-title":"Cancer Res."},{"issue":"35","key":"2026101511073657700_cit28","doi-asserted-by":"publisher","first-page":"5978","DOI":"10.1038\/sj.onc.1207802","article-title":"Evidence of MKK4 Pro-Oncogenic Activity in Breast and Pancreatic Tumors","volume":"23","author":"Wang","year":"2004","journal-title":"Oncogene"},{"issue":"5","key":"2026101511073657700_cit29","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1084\/jem.20141957","article-title":"DUSP4 Deficiency Caused by Promoter Hypermethylation Drives JNK Signaling and Tumor Cell Survival in Diffuse Large B Cell Lymphoma","volume":"212","author":"Schmid","year":"2015","journal-title":"J. Exp. Med."},{"issue":"1","key":"2026101511073657700_cit30","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.celrep.2014.02.045","article-title":"Intrinsic Resistance to MEK Inhibition in KRAS Mutant Lung and Colon Cancer through Transcriptional Induction of ERBB3","volume":"7","author":"Sun","year":"2014","journal-title":"Cell Rep."},{"issue":"7","key":"2026101511073657700_cit31","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/s41422-018-0044-4","article-title":"MAP3K1 and MAP2K4 Mutations Are Associated with Sensitivity to MEK Inhibitors in Multiple Cancer Models","volume":"28","author":"Xue","year":"2018","journal-title":"Cell Res."},{"issue":"9","key":"2026101511073657700_cit32","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2319492121","article-title":"Small-Molecule Inhibition of MAP2K4 Is Synergistic with RAS Inhibitors in KRAS-Mutant Cancers","volume":"121","author":"Jansen","year":"2024","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"5","key":"2026101511073657700_cit33","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1021\/acschembio.6b01060","article-title":"A Chemical Probe Strategy for Interrogating Inhibitor Selectivity Across the MEK Kinase Family","volume":"12","author":"Deibler","year":"2017","journal-title":"ACS Chem. Biol."},{"issue":"10","key":"2026101511073657700_cit34","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1021\/acsmedchemlett.1c00376","article-title":"Rational Design, Optimization, and Biological Evaluation of Novel MEK4 Inhibitors against Pancreatic Adenocarcinoma","volume":"12","author":"Kwong","year":"2021","journal-title":"ACS Med. Chem. Lett."},{"issue":"6","key":"2026101511073657700_cit35","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1002\/cmdc.201900019","article-title":"Synthesis and Biological Evaluation of 3-Arylindazoles as Selective MEK4 Inhibitors","volume":"14","author":"Deibler","year":"2019","journal-title":"ChemMedChem"},{"issue":"25","key":"2026101511073657700_cit36","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1056\/NEJMoa2105281","article-title":"Acquired Resistance to KRASG12C Inhibition in Cancer","volume":"384","author":"Awad","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"2026101511073657700_cit37","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.190","article-title":"Adagrasib: A Landmark in the KRASG12C-Mutated NSCLC","volume":"3","author":"Tian","journal-title":"MedComm"},{"issue":"11","key":"2026101511073657700_cit38","doi-asserted-by":"publisher","first-page":"OF1","DOI":"10.1158\/2159-8290.CD-NB2023-0066","article-title":"Adagrasib\u2019s Efficacy Sustained in KRASG12C NSCLC","volume":"13","year":"2023","journal-title":"Cancer Discov."},{"issue":"49","key":"2026101511073657700_cit39","doi-asserted-by":"publisher","first-page":"15841","DOI":"10.1021\/jacs.6b10589","article-title":"Metabolically Labile Fumarate Esters Impart Kinetic Selectivity to Irreversible Inhibitors","volume":"138","author":"Zaro","year":"2016","journal-title":"J. Am. Chem. Soc."},{"issue":"1","key":"2026101511073657700_cit40","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/nbt1358","article-title":"A Quantitative Analysis of Kinase Inhibitor Selectivity","volume":"26","author":"Karaman","year":"2008","journal-title":"Nat. Biotechnol."},{"issue":"9","key":"2026101511073657700_cit41","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.110441","article-title":"G\u03b113 Loss in Kras\/Tp53 Mouse Model of Pancreatic Tumorigenesis Promotes Tumors Susceptible to Rapamycin","volume":"38","author":"Shields","year":"2022","journal-title":"Cell Rep."},{"key":"2026101511073657700_cit42","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1158\/1535-7163.MCT-25-0483","article-title":"Resistance to the KRASG12D Inhibitor MRTX1133 Is Associated with Increased Sensitivity to BET Inhibition","volume":"25","author":"Principe","year":"2026","journal-title":"Mol. Cancer Ther."},{"issue":"21","key":"2026101511073657700_cit43","doi-asserted-by":"publisher","first-page":"3629","DOI":"10.1158\/0008-5472.CAN-23-3574","article-title":"Targeting BCL2 with Venetoclax Enhances the Efficacy of the KRASG12D Inhibitor MRTX1133 in Pancreatic Cancer","volume":"84","author":"Becker","year":"2024","journal-title":"Cancer Res."},{"issue":"24","key":"2026101511073657700_cit44","doi-asserted-by":"publisher","first-page":"8516","DOI":"10.1158\/1078-0432.CCR-04-0885","article-title":"MAP2K4\/MKK4 Expression in Pancreatic Cancer: Genetic Validation of Immunohistochemistry and Relationship to Disease Course","volume":"10","author":"Xin","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"2026101511073657700_cit45","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.humpath.2018.11.026","article-title":"Clinicopathological and Prognostic Significance of MKK4 and MKK7 in Resectable Pancreatic Ductal Adenocarcinoma","volume":"86","author":"Lu","year":"2019","journal-title":"Hum. Pathol."},{"issue":"11","key":"2026101511073657700_cit46","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1101\/gad.888501","article-title":"MKK7 Is an Essential Component of the JNK Signal Transduction Pathway Activated by Proinflammatory Cytokines","volume":"15","author":"Tournier","year":"2001","journal-title":"Genes Dev."},{"key":"2026101511073657700_cit47","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2024.129914","article-title":"Conserved Gatekeeper Methionine Regulates the Binding and Access of Kinase Inhibitors to ATP Sites of MAP2K1, 4, and 7: Clues for Developing Selective Inhibitors","volume":"112","author":"Yumura","year":"2024","journal-title":"Bioorg. Med. Chem. Lett."}],"container-title":["ACS Chemical Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acschembio.6c00580","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/acbcct\/article-pdf\/21\/9\/2466\/68396805\/cb-2026-00580a.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/acbcct\/article-pdf\/21\/9\/2466\/68396805\/cb-2026-00580a.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T15:29:15Z","timestamp":1792078155000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/acbcct\/article\/21\/9\/2466\/5421940\/Exploiting-Acquired-Drug-Resistance-in-Pancreatic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,6]]},"references-count":47,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9,6]]},"published-print":{"date-parts":[[2026,9,18]]}},"URL":"https:\/\/doi.org\/10.1021\/acschembio.6c00580","relation":{},"ISSN":["1554-8929","1554-8937"],"issn-type":[{"value":"1554-8929","type":"print"},{"value":"1554-8937","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,6]]}}}